Lancaster JM - Search Results

1

Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families.

Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F, Faucher MC, Dole K, Karimi S, Foulkes W, Lounis H, Warner E, Goss P, Anderson D, Larsson C, Narod SA, Futreal PA. Phelan CM, et al. Among authors: lancaster jm. Nat Genet. 1996 May;13(1):120-2. doi: 10.1038/ng0596-120. Nat Genet. 1996. PMID: 8673090

2

BRCA2 mutations in primary breast and ovarian cancers.

Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR, Futreal PA. Lancaster JM, et al. Nat Genet. 1996 Jun;13(2):238-40. doi: 10.1038/ng0696-238. Nat Genet. 1996. PMID: 8640235

3

BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1.

Lancaster JM, Carney ME, Gray J, Myring J, Gumbs C, Sampson J, Wheeler D, France E, Wiseman R, Harper P, Futreal PA. Lancaster JM, et al. Br J Cancer. 1998 Dec;78(11):1417-20. doi: 10.1038/bjc.1998.701. Br J Cancer. 1998. PMID: 9836472 Free PMC article.

4

Dideoxy fingerprinting assay for BRCA1 mutation analysis.

Lancaster JM, Berchuck A, Futreal PA, Wiseman RW. Lancaster JM, et al. Mol Carcinog. 1997 Jul;19(3):176-9. Mol Carcinog. 1997. PMID: 9254884

5

Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test.

Lancaster JM, Cochran CJ, Brownlee HA, Evans AC, Berchuck A, Futreal PA, Wiseman RW. Lancaster JM, et al. J Natl Cancer Inst. 1996 Apr 17;88(8):552-4. doi: 10.1093/jnci/88.8.552. J Natl Cancer Inst. 1996. PMID: 8606385 No abstract available.

6

Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers.

Carney ME, Maxwell GL, Lancaster JM, Gumbs C, Marks J, Berchuck A, Futreal PA. Carney ME, et al. Among authors: lancaster jm. J Soc Gynecol Investig. 1998 Sep-Oct;5(5):281-5. doi: 10.1016/s1071-5576(98)00018-5. J Soc Gynecol Investig. 1998. PMID: 9773405

7

Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers.

Pal T, Lee JH, Besharat A, Thompson Z, Monteiro AN, Phelan C, Lancaster JM, Metcalfe K, Sellers TA, Vadaparampil S, Narod SA. Pal T, et al. Among authors: lancaster jm. Clin Genet. 2014 Jan;85(1):49-53. doi: 10.1111/cge.12130. Epub 2013 Mar 21. Clin Genet. 2014. PMID: 23438721 Free PMC article.

8

Frequency of germline and somatic BRCA1 mutations in ovarian cancer.

Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, Deffenbaugh AM, Miron A, Marks JR, Futreal PA, Frank TS. Berchuck A, et al. Among authors: lancaster jm. Clin Cancer Res. 1998 Oct;4(10):2433-7. Clin Cancer Res. 1998. PMID: 9796975

9

Allele loss on chromosome 1p36 in epithelial ovarian cancers.

Alvarez AA, Lambers AR, Lancaster JM, Maxwell GL, Ali S, Gumbs C, Berchuck A, Futreal PA. Alvarez AA, et al. Among authors: lancaster jm. Gynecol Oncol. 2001 Jul;82(1):94-8. doi: 10.1006/gyno.2001.6175. Gynecol Oncol. 2001. PMID: 11426968

10

Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer.

Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A, Wiseman RW, Taylor JA. Lancaster JM, et al. Mol Carcinog. 1996 Nov;17(3):160-2. doi: 10.1002/(SICI)1098-2744(199611)17:3<160::AID-MC8>3.0.CO;2-J. Mol Carcinog. 1996. PMID: 8944076

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

133 results

Search Page